With RFK Jr. nominated for Secretary of the Department of Health & Human Services, these are all the agencies, including the ...

Seattle's Zillow Group announced a new COO, while Vouched hired a new CTO. Fred Hutch created and filled the new title of ...

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision ...

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

The intrigue on Capitol Hill has been fueled by increased public interest in the topic, as some videos of UAPs have become ...

The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

A recent House Oversight hearing with independent journalist Michael Shellenberger, former intelligence agent Luis Elizondo, ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.